Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Oxaliplatin + Capecitabine in Elderly Patients with Advanced Colorectal Cancer
2010-019463-10Phase 2Active
- Sponsor
- San Carlo Hospital
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, oxaliplatin and capecitabine in colorectal cancer (CRC), sponsored by San Carlo Hospital. Primary endpoint: Activity and toxicity of bevacizumab + oxaliplatin + capecitabine. Started May 2010; status: active.
02
Drugs
bevacizumaboxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-019463-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019463-10.